BiotechTube

crizotinib + alectinib + brigatinib + ceritinib + lorlatinib

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ALK-positive NSCLC

Conditions

ALK-positive NSCLC

Trial Timeline

Dec 14, 2020 → Mar 15, 2021

NCT ID
NCT04647110

About crizotinib + alectinib + brigatinib + ceritinib + lorlatinib

crizotinib + alectinib + brigatinib + ceritinib + lorlatinib is a pre-clinical stage product being developed by Pfizer for ALK-positive NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT04647110. Target conditions include ALK-positive NSCLC.

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04647110Pre-clinicalCompleted

Competing Products

9 competing products in ALK-positive NSCLC

See all competitors
ProductCompanyStageHype Score
Crizotinib + PembrolizumabMerckPhase 1
21
Ceritinib (LDK378) + NivolumabNovartisPhase 1
33
CeritinibNovartisPhase 2
27
CeritinibNovartisPhase 2
35
ceritinib + warfarin + midazolamNovartisPhase 1
29
PF-02341066 + Rifampin + ItraconazolePfizerPhase 1
29
LortlatinibPfizerPre-clinical
26
LorlatinibPfizerPhase 2
31
PF-06463922 + CrizotinibPfizerPhase 1/2
32